Limp Statins

  • by: |
  • 01/19/2012

Non-communicable diseases (NCDs) are the leading cause of death and disease worldwide, killing more than 36 million people in 2008, with nearly 80% of these deaths occurring in low- and middle-income countries. And they’re projected to increase by 15% globally between 2010 and 2020.

The good news is the world’s recognition of the problem (World Health Organization’s Action Plan on NCDs, the Moscow Ministerial Declaration, the United Nations Civil Society Hearings in New York).

The bad news is that this could easily become next great insidious opportunity for drug counterfeiters. The false profits of fake statins, beta-blockers, ace inhibitors, etc. could be huge – as would the public health consequences.

And these counterfeit medicines will flood the developing world unless public health officials, law enforcement, and manufacturers get a jump on the issue. The way to combat this frightening problem is to stop it before it starts.

Unfortunately (at least to date) this has not been the general approach to addressing counterfeit medicines.  Meetings and discussion must now morph into planning and action. As Peggy Hamburg said last year at a meeting at the Council on Foreign Relations, the new reality for food and drug regulation is that it’s global and should be a topic for conversation at the next meeting of the G20. She warned that the recent crises in both food and drug safety will only repeat themselves unless regulatory agencies from around the world work in closer and more regular partnership.


We mustn’t allow Lipitor to become the new Viagra. Counterfeiting doesn’t need a new posterchild. It needs to be fought – and defeated.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog